Moreover, these patients showed high levels of AAT, TF, HTN and PTAFR; Group 3 included 2 FSGS patients with levels of CALB2 < 6.4 ng/ml, levels of MRPL17 < 139.29 pg/ml and detection of HTN; Group 4 included 6 patients (4 MCD, 2 FSGS) with levels of CALB2 < 6.4 ng/ml, levels of MRPL17 < 139.29 pg/ml and no detection of HTN. This evidence concerns the gene MRPL17 and hypertensive disorder.